Document:

ASSIGNMENT AGREEMENT

 

THIS ASSIGNMENT AGREEMENT (the “Agreement”)
is made and entered into as of, December 20, 2011, with effective date of January 1, 2007 (the “Effective Date”),
by and between BrainStorm Cell Therapeutics Inc., a company incorporated under the laws of the State of Delaware, having its corporate
headquarters at East 59th Street, New York, NY 10019 USA (the “Assignor”), and Brainstorm Cell Therapeutics
Ltd., a limited liability company incorporated under the laws of the State of Israel, having a place of business at 12 Bazel Street,
Street, Petach Tikva, Israel 49170 (the “Assignee”).

 

WHEREAS, the Assignor is a party
to that certain Second Amended and Restated and License Agreement dated July 26, 2007, effective July 12, 2004, by and between
the Assignor and Ramot at Tel Aviv University Ltd. (“Ramot”), as amended on December 24, 2009 (including all
exhibits and schedules thereto and all transactions contemplated thereunder, the “License Agreement”);

 

WHEREAS, the Assignor wishes
to assign and transfer any and all of its rights, interests, titles, liabilities and obligations (the “Assignor’s
Rights”) under the License Agreement to the Assignee, and respectively, the Assignee wishes to assume the Assignor’s
Rights thereunder;

 

NOW, THEREFORE, for good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor and Assignee, intending to be legally
bound hereby, hereby agree as follows:

 

		1.	The Assignor absolutely and irrevocably assigns and transfers all of Assignor’s Rights under
the License Agreement to the Assignee, and the Assignee hereby agrees to assume the same, all from the Effective Date including,
inter alia, the ownership rights of Assignor in the joint patent application WO2009/144718 relating to MESENCHYMAL STEM CELLS FOR
THE TREATMENT OF CNS DISEASES and all National Phase, Continuation and Divisional Applications therefrom.

 

		2.	The Assignor hereby undertakes towards Ramot to be a guarantor of all obligations of the Assignee
under the License Agreement. Should Assignee be in breach of the License Agreement Ramot shall be entitled to approach Assignor
demanding compliance with the License Agreement.

 

		3.	This Agreement shall be governed by and construed according to the laws of the State of Israel,
without regard to the conflict of laws provision thereof.

 

		4.	Each of the parties hereto shall perform such further acts and execute such further documents as
may reasonably be necessary to carry out and give full effect to the provisions of this Agreement and the intentions of the parties
as reflected thereby.

 

		5.	This Agreement may be executed in any
number of counterparts, each of which shall be deemed an original and enforceable against the parties actually executing such counterpart,
and all of which together shall constitute one and the same instrument.

 

    	 

    	 

    
IN WITNESS WHEREOF, the parties have signed this Agreement effective
as of the Effective Date:

 

	Assignor:	 	Assignee:
	 	 	 
	Brainstorm Cell Therapeutics Inc.	 	Brainstorm Cell Therapeutics Ltd.
	 	 	 
	By: 	/s/ Adrian Harel	 	By: 	/s/ Liat Sossover
	Name:   Adrian Harel	 	Name:    Liat Sossover
	Title:     CEO	 	Title       CFO
	              20/12/2011	 	               Dec 20, 2011

 

		

 

 

The undersigned, Ramot at Tel Aviv University
Ltd., in accordance with Section 14.10 to the License Agreement hereby provides its consent to the assignment of the License Agreement,
in accordance with the terms above and agrees to execute such documents as may reasonably be necessary to carry out and give full
effect to the provisions of this Agreement.

 

	/s/ Avi Nataneli	 	/s/ Ze’ev Weinfeld	 	21/12/2011
	Ramot at Tel Aviv University Ltd.	 	Date

	Avi Nataneli	 	Ze’ev Weinfeld, Ph.D.
	Chief Financial Officer	 	CEOFIRST AMENDMENT
TO AGREEMENT 

THIS FIRST
AMENDMENT TO AGREEMENT (“Amendment”) is made as of December 31, 2011 by and among Prof. Avi Israeli, Hadasit
Medical Research Services and Development Ltd. and BrainStorm Cell Therapeutics Inc. (together, the “Parties”).

WHEREAS, the
Parties have entered into that certain Agreement dated April 13th, 2010 (the “Agreement”); and

WHEREAS, it
is and was the intention of the Parties that the Options (as defined in the Agreement) be granted initially on April 13, 2010 and
then also granted upon each anniversary of April 13, 2010 until the Agreement is terminated (and subject to other terms and conditions
stated in the Agreement), and the Parties wish to clarify the Agreement accordingly.

NOW, THEREFORE,
in consideration of the mutual promises herein and for other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Parties hereby agree as follows:

1.       That
Section 3.1 of the Agreement is amended and restated in its entirety as follows: 

3.1     options or warrants
to purchase up to 200,000 (two hundred thousand) (subject to adjustment for stock splits, stock dividends, reverse stock splits,
recapitalizations and the like, but for the avoidance of doubt, such options or warrants shall not have any anti-dilution adjustments
or protections and shall not have preemptive rights attach to such options or warrants, and the holder of the options or warrants
shall not be granted any preemptive rights) shares of the Company’s common stock, par value USD $0.00005, to be granted
on the date of this Agreement (April 13, 2010) and upon each anniversary of the date of this Agreement (i.e. on April 12, 2011,
April 12, 2012, April 12, 2013, and so on) until the Agreement is terminated, with par value USD $0.00005 each, at an exercise
price per share of USD $0.00005 per share of Company common stock (the “Options”) as follows: Prof. Israeli
shall be granted options to purchase 166,666 (one hundred sixty six thousand, six hundred and sixty six) shares of the Company’s
common stock, par value USD $0.00005 each, and Hadasit shall be granted warrants to purchase 33,334 (thirty three thousand three
hundred and thirty four) shares of the Company’s common stock, par value USD $0.00005 each. 

2.       That Section 3.2
of the Agreement is amended and restated in its entirety as follows: 

3.2     The Options shall
terminate upon the earliest of: (i) the 10 year anniversary of the grant date of such Option; (ii) immediately prior to a sale
of all or substantially all of the shares of the Company in a merger and/or acquisition transaction; or (iii) six (6) months following
the termination of the Agreement (the “Termination Date”). Options not exercised by such time shall become null
and void.

    	 

    	 

    

 

3.         That Section
3.3 of the Agreement is amended and restated in its entirety as follows:

3.3       The Options shall
vest and become exercisable in twelve (12) consecutive equal monthly amounts at the end of each calendar month following the date
of grant (as determined in accordance with Section 3.1 of this Agreement) of such Option. For clarity, in the event of termination
of this Agreement, all options or warrants for the purchase of common stock that have vested and become exercisable under Options
prior to the date of termination of this Agreement, shall be made available to be exercised immediately after termination thereof.
Vesting shall be subject to (i) the provisions of Company’s 2004 Global Share Option Plan, (ii) a resolution of the Board
of Directors of the Company, and (iii) the execution by the parties of an option agreement or warrant and any other document required
by the Company. 

4.        This
Amendment may be executed in counterparts which, when taken together, shall constitute one and the same agreement. 

 

[Signatures on following page]

    	 

    	 

    

 

IN WITNESS
WHEREOF, the parties have executed this Amendment as of the date first written above. 

	 	BRAINSTORM CELL THERAPEUTICS INC.
	 	 
	 	By:  /s/ Liat Sossover
	 	Name: Liat Sossover
	 	Title: Chief Financial Officer
	 	 
	 	/s/ Avi Israeli
	 	Prof. Avi Israeli
	 	 
	 	HADASIT MEDICAL RESEARCH
	 	SERVICES AND DEVELOPMENT LTD.
	 	 
	 	By:  /s/ Dr. Einat Zisman
	 	Name:  Dr. Einat Zisman
	 	Title:   CEOTHIS WARRANT
AND THE SHARES OF COMMON STOCK ISSUED UPON ITS

EXERCISE ARE
SUBJECT TO THE RESTRICTIONS ON 

            TRANSFER
SET FORTH IN SECTION 4 OF THIS WARRANT       

 

	Warrant No.: 2010-4	Number of Shares: 33,334
	 	(subject to adjustment)
	Date of Issuance: April 13, 2010	 

 

BRAINSTORM CELL
THERAPEUTICS, INC.

 

Common Stock Purchase
Warrant

 

(Void after April
13, 2020)

 

BrainStorm Cell Therapeutics, Inc., a Delaware
corporation (the “Company”), for value received, hereby certifies that Hadasit Medical Research Services and Development
Ltd., or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth
below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m.
(New York time) on April 13, 2020 (the “Expiration Date”), 33,334 shares of Common Stock, $0.00005 par value per share,
of the Company, at a purchase price of $0.00005 per share. The shares purchasable upon exercise of this Warrant, and the purchase
price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as
the “Warrant Shares” and the “Purchase Price,” respectively.

 

1.        Exercise.

 

(a)          This
Warrant may be exercised by the Registered Holder, in whole or in part, by surrendering this Warrant, with the purchase form appended
hereto as Exhibit I duly executed by the Registered Holder or by the Registered Holder’s duly authorized attorney,
at the principal office of the Company, or at such other office or agency as the Company may designate, accompanied by payment
in full, in lawful money of the United States, of the Purchase Price payable in respect of the number of Warrant Shares purchased
upon such exercise; provided however that this Warrant may only be exercised as to vested Warrant Shares, and shall vest and become
exercisable as follows: in twelve (12) consecutive equal monthly amounts at the end of each calendar month starting April 30, 2010
such that all Warrant Shares are vested in full on March 31, 2011 (the “Fully Vested Date”), unless the Agreement dated
April 13, 2010 by and among Prof. Avi Israeli, the Registered Holder and the Company (the “Agreement”) is terminated
prior to the Fully Vested Date, in which case no further Warrant Shares shall vest on or after the date of such termination. Upon
termination of the Agreement vesting shall cease and the Registered Holder shall be entitled to exercise this Warrant only with
respect to the portion of the Warrant Shares that shall have vested prior to the date of termination of the Agreement, rounded
to the nearest number without decimal. The Warrant shall be valid until and may be exercised only on or before the earliest of
the following: (i) immediately prior to a sale of all or substantially all of the shares of the Company in a merger and/or acquisition
transaction; (ii) the Expiration Date; or (iii) six (6) months following the termination of the Agreement. Immediately after such
date all unexercised Warrant Shares shall expire and be forfeited, and this Warrant shall terminate.

 

    	 

    	 

    

 

(b)         The
Registered Holder may, at its option, elect to pay some or all of the Purchase Price payable upon an exercise of this Warrant by
canceling a portion of this Warrant exercisable for such number of Warrant Shares as is determined by dividing (i) the total
Purchase Price payable in respect of the number of Warrant Shares being purchased upon such exercise by (ii) the excess of
the Fair Market Value per share of Common Stock (as defined below) as of the Exercise Date (as defined in subsection 1(c) below)
over the Purchase Price per share. If the Registered Holder wishes to exercise this Warrant pursuant to this method of payment
with respect to the maximum number of Warrant Shares purchasable pursuant to this method, then the number of Warrant Shares so
purchasable shall be equal to the total number of Warrant Shares, minus the product obtained by multiplying (x) the total
number of Warrant Shares by (y) a fraction, the numerator of which shall be the Purchase Price per share and the denominator
of which shall be the Fair Market Value per share of Common Stock as of the Exercise Date. The Fair Market Value per share of Common
Stock shall be determined as follows:

 

(i)          If
the Common Stock is listed on a national securities exchange or another nationally recognized trading system as of the Exercise
Date, the Fair Market Value per share of Common Stock shall be deemed to be the average of the high and low reported sale prices
per share of Common Stock thereon on the trading day immediately preceding the Exercise Date (provided that if no such price is
reported on such day, the Fair Market Value per share of Common Stock shall be determined pursuant to clause (ii)).

 

(ii)         If
the Common Stock is not listed on a national securities exchange or another nationally recognized trading system as of the Exercise
Date, the Fair Market Value per share of Common Stock shall be deemed to be the amount most recently determined by the Board of
Directors to represent the fair market value per share of the Common Stock (including without limitation a determination for purposes
of granting Common Stock options or issuing Common Stock under an employee benefit plan of the Company); and, upon request of the
Registered Holder, the Board of Directors (or a representative thereof) shall promptly notify the Registered Holder of the Fair
Market Value per share of Common Stock. Notwithstanding the foregoing, if the Board of Directors has not made such a determination
within the three-month period prior to the Exercise Date, then (A) the Board of Directors shall make a determination of the
Fair Market Value per share of the Common Stock within 15 days of a request by the Registered Holder that it do so, and (B) the
exercise of this Warrant pursuant to this subsection 1(b) shall be delayed until such determination is made.

 

(c)          Each
exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which this
Warrant shall have been surrendered to the Company as provided in subsection 1(a) above (the “Exercise Date”). At such
time, the person or persons in whose name or names any certificates for Warrant Shares shall be issuable upon such exercise as
provided in subsection 1(d) below shall be deemed to have become the holder or holders of record of the Warrant Shares represented
by such certificates.

 

    	- 2 -

    	 

    

 

(d)          As
soon as practicable after the exercise of this Warrant in full or in part, and in any event within 10 days thereafter, the Company,
at its expense, will cause to be issued in the name of, and delivered to, the Registered Holder, or as such Holder (upon payment
by such Holder of any applicable transfer taxes) may direct:

 

(i)          a
certificate or certificates for the number of full Warrant Shares to which the Registered Holder shall be entitled upon such exercise
plus, in lieu of any fractional share to which the Registered Holder would otherwise be entitled, cash in an amount determined
pursuant to Section 3 hereof; and

 

(ii)         in
case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor, calling in the aggregate on
the face or faces thereof for the number of Warrant Shares equal (without giving effect to any adjustment therein) to the number
of such shares called for on the face of this Warrant minus the sum of (a) the number of such shares purchased by the Registered
Holder upon such exercise plus (b) the number of Warrant Shares (if any) covered by the portion of this Warrant cancelled
in payment of the Purchase Price payable upon such exercise pursuant to subsection 1(b) above.

 

2.      
 Adjustments.

 

(a)          Adjustment
for Stock Splits and Combinations. If the Company shall at any time or from time to time after the date on which this Warrant
was first issued (the “Original Issue Date”) effect a subdivision of the outstanding Common Stock, the Purchase Price
then in effect immediately before that subdivision shall be proportionately decreased. If the Company shall at any time or from
time to time after the Original Issue Date combine the outstanding shares of Common Stock, the Purchase Price then in effect immediately
before the combination shall be proportionately increased. Any adjustment under this paragraph shall become effective at the close
of business on the date the subdivision or combination becomes effective.

 

(b)          Adjustment
for Certain Dividends and Distributions. In the event the Company at any time, or from time to time after the Original Issue
Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend
or other distribution payable in additional shares of Common Stock, then and in each such event the Purchase Price then in effect
immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have
been fixed, as of the close of business on such record date, by multiplying the Purchase Price then in effect by a fraction:

 

(1)         the
numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of
such issuance or the close of business on such record date, and

 

(2)         the
denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of
such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such
dividend or distribution;

 

    	- 3 -

    	 

    

 

provided, however, if such record date shall have
been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the Purchase
Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Purchase Price shall be
adjusted pursuant to this paragraph as of the time of actual payment of such dividends or distributions.

 

(c)          Adjustment
in Number of Warrant Shares. When any adjustment is required to be made in the Purchase Price pursuant to subsections 2(a)
or 2(b), the number of Warrant Shares purchasable upon the exercise of this Warrant shall be changed to the number determined by
dividing (i) an amount equal to the number of shares issuable upon the exercise of this Warrant immediately prior to such
adjustment, multiplied by the Purchase Price in effect immediately prior to such adjustment, by (ii) the Purchase Price in
effect immediately after such adjustment.

 

(d)          Adjustments
for Other Dividends and Distributions. In the event the Company at any time or from time to time after the Original Issue Date
shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other
distribution payable in securities of the Company (other than shares of Common Stock) or in cash or other property (other than
cash out of earnings or earned surplus, determined in accordance with generally accepted accounting principles), then and in each
such event provision shall be made so that the Registered Holder shall receive upon exercise hereof, in addition to the number
of shares of Common Stock issuable hereunder, the kind and amount of securities of the Company and/or cash and other property which
the Registered Holder would have been entitled to receive had this Warrant been exercised into Common Stock on the date of such
event and had the Registered Holder thereafter, during the period from the date of such event to and including the Exercise Date,
retained any such securities receivable, giving application to all adjustments called for during such period under this Section
2 with respect to the rights of the Registered Holder.

 

(e)          Adjustment
for Mergers or Reorganizations, etc. If there shall occur any reorganization, recapitalization, consolidation or merger involving
the Company in which the Common Stock is converted into or exchanged for securities, cash or other property (other than a transaction
covered by subsections 2(a), 2(b) or 2(d)), then, following any such reorganization, recapitalization, consolidation or merger,
the Registered Holder shall receive upon exercise hereof the kind and amount of securities, cash or other property which the Registered
Holder would have been entitled to receive if, immediately prior to such reorganization, recapitalization, consolidation or merger,
the Registered Holder had held the number of shares of Common Stock subject to this Warrant.  In any such case, appropriate
adjustment (as determined in good faith by the Board of Directors of the Company) shall be made in the application of the provisions
set forth herein with respect to the rights and interests thereafter of the Registered Holder, to the end that the provisions set
forth in this Section 2 (including provisions with respect to changes in and other adjustments of the Purchase Price) shall thereafter
be applicable, as nearly as reasonably may be, in relation to any securities, cash or other property thereafter deliverable upon
the exercise of this Warrant.

 

    	- 4 -

    	 

    

 

(f)          Certificate
as to Adjustments. Upon the occurrence of each adjustment or readjustment of the Purchase Price pursuant to this Section 2,
the Company at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish
to the Registered Holder a certificate setting forth such adjustment or readjustment (including the kind and amount of securities,
cash or other property for which this Warrant shall be exercisable and the Purchase Price) and showing in detail the facts upon
which such adjustment or readjustment is based. The Company shall, upon the written request at any time of the Registered Holder,
furnish or cause to be furnished to the Registered Holder a certificate setting forth (i) the Purchase Price then in effect
and (ii) the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would
be received upon the exercise of this Warrant.

 

3.       Fractional
Shares. The Company shall not be required upon the exercise of this Warrant to issue any fractional shares, but shall make
an adjustment therefor in cash on the basis of the Fair Market Value per share of Common Stock, as determined pursuant to subsection
1(b) above.

 

4.       Requirements
for Transfer.

 

(a)          This
Warrant and the Warrant Shares shall not be sold or transferred unless either (i) they first shall have been registered under
the Securities Act of 1933, as amended (the “Act”), or (ii) the Company first shall have been furnished with an
opinion of legal counsel, reasonably satisfactory to the Company, to the effect that such sale or transfer is exempt from the registration
requirements of the Act.

 

(b)          Notwithstanding
the foregoing, no registration or opinion of counsel shall be required for (i) a transfer by a Registered Holder which is
a corporation to a wholly owned subsidiary of such corporation, a transfer by a Registered Holder which is a partnership to a partner
of such partnership or a retired partner of such partnership or to the estate of any such partner or retired partner, or a transfer
by a Registered Holder which is a limited liability company to a member of such limited liability company or a retired member or
to the estate of any such member or retired member, provided that the transferee in each case agrees in writing to be subject to
the terms of this Section 4, or (ii) a transfer made in accordance with Rule 144 under the Act.

 

(c)          Each
certificate representing Warrant Shares shall bear a legend substantially in the following form:

 

“The securities represented by this certificate
have not been registered under the Securities Act of 1933, as amended, and may not be offered, sold or otherwise transferred, pledged
or hypothecated unless and until such securities are registered under such Act or an opinion of counsel satisfactory to the Company
is obtained to the effect that such registration is not required.”

 

5.         No
Impairment. The Company will not, by amendment of its charter or through reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the
taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of this Warrant against
impairment.

 

    	- 5 -

    	 

    

 

6.       Notices
of Record Date, etc. In the event:

 

(a)          the
Company shall take a record of the holders of its Common Stock (or other stock or securities at the time deliverable upon the exercise
of this Warrant) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any
right to subscribe for or purchase any shares of stock of any class or any other securities, or to receive any other right; or

 

(b)          of
any capital reorganization of the Company, any reclassification of the Common Stock of the Company, any consolidation or merger
of the Company with or into another corporation (other than a consolidation or merger in which the Company is the surviving entity
and its Common Stock is not converted into or exchanged for any other securities or property), or any transfer of all or substantially
all of the assets of the Company; or

 

(c)          of
the voluntary or involuntary dissolution, liquidation or winding-up of the Company,

 

then, and in each such case, the Company will
mail or cause to be mailed to the Registered Holder a notice specifying, as the case may be, (i) the record date for such dividend,
distribution or right, and the amount and character of such dividend, distribution or right, or (ii) the effective date on which
such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up is to take place,
and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other stock or securities at the
time deliverable upon the exercise of this Warrant) shall be entitled to exchange their shares of Common Stock (or such other stock
or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger,
transfer, dissolution, liquidation or winding-up. Such notice shall be mailed at least ten days prior to the record date or effective
date for the event specified in such notice.

 

7.         Reservation
of Stock. The Company will at all times reserve and keep available, solely for issuance and delivery upon the exercise of this
Warrant, such number of Warrant Shares and other securities, cash and/or property, as from time to time shall be issuable upon
the exercise of this Warrant.

 

8.         Exchange
of Warrants. Upon the surrender by the Registered Holder, properly endorsed, to the Company at the principal office of the
Company, the Company will, subject to the provisions of Section 4 hereof, issue and deliver to or upon the order of such Holder,
at the Company’s expense, a new Warrant or Warrants of like tenor, in the name of the Registered Holder or as the Registered
Holder (upon payment by the Registered Holder of any applicable transfer taxes) may direct, calling in the aggregate on the face
or faces thereof for the number of shares of Common Stock (or other securities, cash and/or property) then issuable upon exercise
of this Warrant.

 

    	- 6 -

    	 

    

 

9.       Replacement
of Warrants. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation
of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably
required) in an amount reasonably satisfactory to the Company, or (in the case of mutilation) upon surrender and cancellation of
this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor.

 

10.     Transfers,
etc.

 

(a)          The
Company will maintain a register containing the name and address of the Registered Holder of this Warrant. The Registered Holder
may change its or his address as shown on the warrant register by written notice to the Company requesting such change.

 

(b)          Subject
to the provisions of Section 4 hereof, this Warrant and all rights hereunder are transferable, in whole or in part, upon surrender
of this Warrant with a properly executed assignment (in the form of Exhibit II hereto) at the principal office of the
Company.

 

(c)          Until
any transfer of this Warrant is made in the warrant register, the Company may treat the Registered Holder as the absolute owner
hereof for all purposes; provided, however, that if and when this Warrant is properly assigned in blank, the Company
may (but shall not be obligated to) treat the bearer hereof as the absolute owner hereof for all purposes, notwithstanding any
notice to the contrary.

 

11.      Mailing
of Notices, etc. All notices and other communications from the Company to the Registered Holder shall be mailed by first-class
certified or registered mail, postage prepaid, to the address last furnished to the Company in writing by the Registered Holder.
All notices and other communications from the Registered Holder or in connection herewith to the Company shall be mailed by first-class
certified or registered mail, postage prepaid, to the Company at its principal office set forth below. If the Company should at
any time change the location of its principal office to a place other than as set forth below, it shall give prompt written notice
to the Registered Holder and thereafter all references in this Warrant to the location of its principal office at the particular
time shall be as so specified in such notice.

 

12.      No
Rights as Stockholder. Until the exercise of this Warrant, the Registered Holder shall not have or exercise any rights by virtue
hereof as a stockholder of the Company. Notwithstanding the foregoing, in the event (i) the Company effects a split of the
Common Stock by means of a stock dividend and the Purchase Price of and the number of Warrant Shares are adjusted as of the date
of the distribution of the dividend (rather than as of the record date for such dividend), and (ii) the Registered Holder
exercises this Warrant between the record date and the distribution date for such stock dividend, the Registered Holder shall be
entitled to receive, on the distribution date, the stock dividend with respect to the shares of Common Stock acquired upon such
exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on the record date for such
stock dividend.

 

    	- 7 -

    	 

    

 

13.         Change
or Waiver. Any term of this Warrant may be changed or waived only by an instrument in writing signed by the party against which
enforcement of the change or waiver is sought.

 

14.         Section
Headings. The section headings in this Warrant are for the convenience of the parties and in no way alter, modify, amend, limit
or restrict the contractual obligations of the parties.

 

15.         Governing
Law. This Warrant will be governed by and construed in accordance with the internal laws of the State of Delaware (without
reference to the conflicts of law provisions thereof).

 

    	- 8 -

    	 

    

 

EXECUTED as of the date set forth below.

 

	 	BRAINSTORM CELL THERAPEUTICS, INC.
	 	 
	 	By:   Adrian Harel; Liat Sossover
	 	 
	 	Title:  Acting CEO; CFO
	 	 
	 	Date:  1/17/2012

 

[Corporate Seal]

 

ATTEST:

 

Dr. Einat Zisman

CEO

Hadasit Medical Research Services & Development Ltd.

2/1/2012

 

    	- 9 -

    	 

    

 

EXHIBIT I

 

PURCHASE FORM

 

	To:_________________	Dated:____________

 

The undersigned, pursuant to the provisions
set forth in the attached Warrant (No. ___), hereby irrevocably elects to purchase (check applicable box):

 

		0	_____ shares of the Common Stock covered by such Warrant; or

 

		0	the maximum number of shares of Common Stock covered by such Warrant pursuant to the cashless exercise procedure set forth
in Section 1(b).

 

The undersigned herewith makes payment of the
full purchase price for such shares at the price per share provided for in such Warrant, which is $________. Such payment takes
the form of (check applicable box or boxes):

 

		0	$______ in lawful money of the United States; and/or

 

		0	the cancellation of such portion of the attached Warrant as is exercisable for a total of _____ Warrant Shares (using a Fair
Market Value of $_____ per share for purposes of this calculation); and/or

 

		0	the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in Section 1(b),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in Section 1(b).

 

	 	Signature:	 	 
	 	 	 	 
	 	Address:	 	 
	 	 	 	 
	 	 	 	 

 

    	- 10 -

    	 

    

 

EXHIBIT II

 

ASSIGNMENT FORM

 

FOR VALUE RECEIVED, ________________________________________
hereby sells, assigns and transfers all of the rights of the undersigned under the attached Warrant (No. ____) with respect to
the number of shares of Common Stock covered thereby set forth below, unto:

 

	Name of Assignee	 	Address	 	No. of Shares
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

	Dated:	 	 	Signature:	 

 

Signature Guaranteed:

 

	By:	 	 

 

The signature should be guaranteed by an eligible
guarantor institution (banks, stockbrokers, savings and loan associations and credit unions with membership in an approved signature
guarantee medallion program) pursuant to Rule 17Ad-15 under the Securities Exchange Act of 1934.

 

    	- 11 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00198-of-00352.parquet"}]]